[antelope1225]

Re: Lentzsch & Niesvizky debate maintenance therapy

by antelope1225 on Fri Aug 14, 2015 2:44 pm

Hi Kent.

Thanks for sending the link to the video. I agree that you might be right for most people, but as you know, there are quite a number of different types of multiple myeloma. My oncologist has told me he thinks that sometime soon, they will divide multiple myeloma up into 4-5 different sub types.

https://myelomabeacon.org/news/2012/05/11/revlimid-lenalidomide-maintenance-therapy-studies-clarify-benefits-and-risks

A subgroup analysis showed that patients treated with Revlimid induction therapy had significantly longer survival if they received Revlimid maintenance, compared to those who received a placebo. The same analysis also showed that Revlimid maintenance did not provide a survival advantage for: patients who were treated with thalidomide induction therapy; patients who had elevated beta-2 microglobulin levels; or patients who achieved a complete response prior to the start of maintenance therapy or placebo.

I had thalidomide induction therapy and had beta-2 microglobulin of 8.5 before my ASCT.

Cathy